A Phase 2 interventional study of gNO in Nontuberculous Mycobacterium Infection, sponsored by Medical University of South Carolina. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by Medical University of South Carolina · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask. Subjects will be treated for 3 weeks (5 days per week) and followed monthly for 3 months.
6,688 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 10 is below the median of 120 across 4,201 interventional studies indexed under Infections.
Browse Infections studies →Medical University of South Carolina is the lead sponsor of 852 studies on the registry; 165 are open to participants now.
Of its 128 completed or terminated interventional studies of FDA-regulated products, 101 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects are >18 years of age and able to provide informed consent.
Subjects have NTM lung disease as defined by each of the following:
Sputum cultures positive for NTM (MAC or M abscessus) Radiologic studies that demonstrate features consistent with disease such as nodular bronchiectasis and/or cavities Symptoms consistent with disease including respiratory (e.g. cough, sputum production, hemoptysis, chest pain) and constitutional (e.g. fevers, night sweats, fatigue, myalgias, arthralgias, weight loss) Subjects are able to produce sputum for culture (either spontaneous or induced).
Subjects have a history of persistently positive sputum cultures for NTM defined as >4 number of cultures over 24 months with >75% positive AND a positive culture in the last 3 months.
Clinically stable with no significant changes in health status within 14 days prior to Screening or Day 1 Subjects are willing and able to perform requirements of the study.
Exclusion Criteria:
Smoking history in the prior 6 months Significant hemoptysis within 30 days prior to screening (>5 ml of blood in one coughing episode or >30 ml of blood in a 24 hour period) Forced expiratory volume at one second (FEV1) \<40% of predicted On supplemental oxygen or SaO2 \<90% at screening or Day 1, or within 30 days prior to enrollment.
Known cardiac (left heart) insufficiency (defined as LVEF \<35%) prior to screening Known pulmonary hypertension Known or suspected hemoglobinopathy Initiation of NTM treatment regimen or a change in the regimen was made in the prior 6 months. Subjects on active treatment can be enrolled if they have been on a stable anti-NTM regimen for at least 6 months.
Initiation of new chronic therapy within 4 weeks prior to screening Use of drugs known to increase methemoglobin (see 12.2.7) at screening
Any of the following abnormal lab values at screening:
6-GPD deficiency Hemoglobin \<10g/dl Platelet count \<100,000/mm3 Prothrombin time international ratio (INR) >1.5 Abnormal liver function defined as any two of the following ALT >3x ULN AST >3x ULN ALP >3x ULN GGT >3x ULN
Abnormal renal function defined as:
Calculated Creatinine Clearance \<50 ml (as calculated by Cockcroft/Gault)
For women of child bearing potential:
Positive pregnancy test at screening or Lactating or Unwilling to practice a medically acceptable form of contraception from screening to Day 15 (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent) Use of an investigational drug within 30 days prior to screening Intravenous or oral steroids (>10 mg/d prednisone equivalent) in the 14 days prior to screening Any condition that the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the subject.
Subjects will be receiving nitric oxide every week day for 3 weeks.
Drug: gNO
This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment. Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months. The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires.
Percent Patients With Negative Sputum Culture
Sputum culture will be assessed for any sputum growth. A negative culture represents no mycobacterial growth.
Time frame: End of Treatment (Day 15)
Number of Participants With Treatment Related Adverse Events as Assessed by the CTCAE (Common Terminology Criteria for Adverse Events)
Adverse Events will be assessed by patient reporting and routine lab work
Time frame: Treatment Day 1 through End of Treatment (3 Months)
Number of Participants With a Reduction in Semiquantitative Cultures
Semiquantitative Culture Score is an assessment of bacterial burden with a lower score suggesting a lesser bacterial burden. The Semiquantitative Culture Score at Day 15 was compared to baseline, and a reduction in the Semiquantitative Culture Score suggests a reduced bacterial burden with treatment. Cultures were reported as positive if growth occurs in broth medium only; growth on broth medium plus solid medium cultures with countable colonies will be reported as 0-49 colonies, 1+; solid medium growth with 50-99 colonies, 2+; solid medium growth with 100-199 colonies; 3+, solid medium growth with 200-299 colonies; and 4+, solid medium growth with at least 300 colonies. For data analysis, each culture was scored as follows: 0, no growth in broth or solid medium; 1, broth medium growth only; 2, countable colonies (\<50 colonies) on solid medium; and 3-6, 1+ to 4+ growth on solid medium, respectively.
Time frame: At day 15 from baseline
| Milestone | Inhaled Nitric Oxide (gNO) |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Sputum culture will be assessed for any sputum growth. A negative culture represents no mycobacterial growth.
| percentage of participants | Inhaled Nitric Oxide (gNO) |
|---|---|
| Percent Patients With Negative Sputum Culture | 40 |
Adverse Events will be assessed by patient reporting and routine lab work
| Participants | Inhaled Nitric Oxide (gNO) |
|---|---|
| Number of Participants With Treatment Related Adverse Events as Assessed by the CTCAE (Common Terminology Criteria for Adverse Events) | 6 |
Semiquantitative Culture Score is an assessment of bacterial burden with a lower score suggesting a lesser bacterial burden. The Semiquantitative Culture Score at Day 15 was compared to baseline, and a reduction in the Semiquantitative Culture Score suggests a reduced bacterial burden with treatment. Cultures were reported as positive if growth occurs in broth medium only; growth on broth medium plus solid medium cultures with countable colonies will be reported as 0-49 colonies, 1+; solid medium growth with 50-99 colonies, 2+; solid medium growth with 100-199 colonies; 3+, solid medium growth with 200-299 colonies; and 4+, solid medium growth with at least 300 colonies. For data analysis, each culture was scored as follows: 0, no growth in broth or solid medium; 1, broth medium growth only; 2, countable colonies (\<50 colonies) on solid medium; and 3-6, 1+ to 4+ growth on solid medium, respectively.
| participants | Inhaled Nitric Oxide (gNO) |
|---|---|
| Number of Participants With a Reduction in Semiquantitative Cultures | 4 |
Collected over Patients were assessed for AE's throughout the duration of the study, approximately 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Nitric Oxide (gNO) | 0/10 (0%) | 1/10 (10%) | 6/10 (60%) |
| Event | Inhaled Nitric Oxide (gNO) |
|---|---|
| Transient Ischemic AttackVascular disorders | 1/10 |
| Event | Inhaled Nitric Oxide (gNO) |
|---|---|
| HemoptysisRespiratory, thoracic and mediastinal disorders | 3/10 |
| HeadacheNervous system disorders | 2/10 |
| Pain/pleurisyNervous system disorders | 2/10 |
| WheezingRespiratory, thoracic and mediastinal disorders | 2/10 |
| Chest tightnessCardiac disorders | 1/10 |
| Cough increasedRespiratory, thoracic and mediastinal disorders | 1/10 |
| HematocheziaGastrointestinal disorders | 1/10 |
| NauseaGastrointestinal disorders | 1/10 |
| Night sweatsGeneral disorders | 1/10 |
| ShinglesInfections and infestations | 1/10 |
| Age, Continuous(years) | Inhaled Nitric Oxide (gNO) |
|---|---|
| Mean | 47.7 ± 24.6 |
| Sex: Female, Male(Participants) | Inhaled Nitric Oxide (gNO) |
|---|---|
| Female | 3 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | Inhaled Nitric Oxide (gNO) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Inhaled Nitric Oxide (gNO) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Inhaled Nitric Oxide (gNO) |
|---|---|
| United States | 10 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina